Skip to main content

About us

BioSpero, founded in 2019, is a biotechnology company leading a new paradigm in drug development through microphysiological systems (MPS) and organ-on-a-chip technologies. As next-generation alternatives to animal testing, our platforms deliver human-relevant, high-fidelity models that enable more accurate, ethical, and efficient preclinical evaluation.
We design, develop, and manufacture cutting-edge MPS platforms that assess the toxicity and efficacy of compounds across pharmaceuticals, cosmetics, functional foods, and other regulated sectors. Our systems are engineered to support predictive clinical insights, helping clients make better decisions earlier-reducing development risks, timelines, and costs.
At BioSpero, our mission is to empower clients with advanced tools that accelerate innovation, improve success rates, and ensure safer, more effective products reach the market. We are committed to shaping the future of biomedical science through sustained research and technological excellence.

Mission

BioSpero delivers microfluidic solutions to address major challenges in drug discovery and development.
We develop cutting-edge microphysiological platforms to enhance clinical trial prediction by replicating human tissue environments with high precision.

Vision

BioSpero aims to fast-track drug discovery and development through cutting-edge emerging technologies.
We focus on lead compound identification and validation using both conventional and innovative biological approaches.
Our preclinical platforms enable predictive assessment of drug efficacy, safety, and toxicity, helping to accelerate drug development timelines.
By applying the principles of the 4Rs—replacement, reduction, refinement, and rehabilitation—we provide a clinical prediction-based alternative to traditional animal testing.